Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.
Patients on Boehringer Ingelheim drugs for respiratory conditions have the option to enroll with certain health systems to get free access to inhalers embedded with Propeller Health sensors.
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Also, a new deal for Illumina, a cure for Martin Shkreli, a controversial hospital acquisition and another Obamacare deadline approaches.
The clearance permits companies that use medications with GSK's Diskus dry powder inhaler for COPD patients to use Propeller's platform to better understand how COPD patients used their inhaler between appointments.
Pharmaceutical companies are turning to ethnographers to get a better appreciation for the diversity of the patient experience.
Three years ago Boehringer-Ingelheim set up a team called New Business Model and Healthcare Innovation with a mission of looking at everything that was non-therapeutic, because it wanted to see how these technologies would fit into a prescription medicine portfolio once they were de-risked. It has since initiated collaborations with Propeller Health and become a […]
If you’re helping clients navigate big changes—from the surge in GLP-1 demand to AI to the growing pressure to demonstrate ROI – we want your thoughts.
In the grand experiment that is healthcare social media, there have certainly been some hits and misses. The lack of clarity around the ROI in social media for pharmaceutical companies (or anywhere, really) in combination with a lack of comprehensive guidance from the U.S. Food and Drug Administration makes its ground on which drug companies […]
A landmark report on the Global Economic Impact of Dementia finds that Alzheimer's disease and other dementias are exacting a massive toll -- $604 billion in 2010 -- on the global economy, with the problem set to accelerate in coming years.
The Food and Drug Administration (FDA) has joined the ranks of public health agencies reviewing a popular class of blood pressure medicines and its possible link to cancer, despite criticism about using the method of meta-analysis to establish such a link. Researchers at Cleveland, Ohio’s, University Hospitals Harrington-McLaughlin Heart & Vascular Institute blew the whistle […]
Two Ohio-based units of German drugmaker Boehringer Ingelheim will contribute to a $7.75 million settlement with Wisconsin of claims they overcharged its Medicaid program for drugs, according to the Pharmalot blog. The settlement by Roxane Laboratories in Columbus and Ben Venue Laboratories in Bedford — neither admitting wrongdoing or violation — was part of a […]
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
The German parent of Ben Venue and Roxane drug-making facilities in Ohio has launched a $135 million venture fund to foster innovation in the life sciences. Boehringer Ingelheim GmbH of Ingelheim, Germany, started Boehringer Ingelheim Venture Fund to invest in biotech and start-up companies worldwide “that provide ground-breaking therapeutic approaches and technologies to help drive […]
The Ohio Third Frontier program has attracted $3.2 billion in private investment since it began seven years ago, according to a recent report by the Ohio Business Roundtable. The Roundtable is one of the leading proponents of renewing Ohio Third Frontier through a May 2010 ballot initiative.